TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06615219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intergroup contact training
Description: The intervention program uses direct contact and four types of indirect contact as the intervention strategy and general framework, and is divided into three main steps, assessing and reflecting on aging stereotypes, carrying out indirect and direct contact, and evaluating the effectiveness of the intervention. The time period is 12 weeks, with the interventionists comprising the researcher and nursing students. The forms of the intervention include holding mini-lectures, organizing participation in voluntary activities, and nostalgia interviews.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular course training only
Description: The specific process is to sign in the classroom, review the knowledge of the previous class by asking questions, introduce the content of the new class, the teacher explains the knowledge points according to the teaching objectives and teaching content, and finally assigns the post-class homework of the course content. At the end of the experiment, the control group was given compensatory intervention.
Study: NCT04756232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine Challenge
Description: Mecamylamine 20 mg oral pill administered once

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator Challenge
Description: Matching placebo oral pill administered once
Study: NCT06675747

Intervention type: OTHER
Intervention: Ultrasound imaging
Description: To investigate the mechanism of action of occlusal splints, a routinely applied treatment method for myogenic temporomandibular disorders, ultrasound images will be taken from all patients before and after treatment, and measurements will be conducted based on these images.
Study: NCT06626126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ApoB-guided-LLT
Description: Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LDL-C-guided-LLT
Description: Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.
Study: NCT06550388

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional Education
Description: In addition to the traditional course of CBT-I, the PI will provide education and materials regarding the Mediterranean Diet. Patient will be provided with the Mayo Clinic booklet on Mediterranean Diet and asked to increase their daily intake in two categories assessed by the Mini-EAT.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity
Description: In addition to the traditional course of CBT-I, the PI will recommend patient to increase physical activity minutes per week. The increase in physical activity will be based on patient's current level of physical activity.
Study: NCT06605560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: PRP contains a high concentration of platelets obtained by centrifugation of autologous blood. After degranulation of platelets, various growth factors and cytokines are released and accelerate cartilage matrix synthesis, restrain synovial membrane inflammation and promote cartilage healing.
Study: NCT06588101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written informed consent with infographic
Description: Potential participants are provided a visual infographic depicting the key elements of the written consent form in addition to the standard written consent form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written informed consent with infographic
Description: Potential participants are provided a visual infographic depicting the key elements of the written consent form in addition to the standard written consent form.
Study: NCT05777824

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anti-PD-1 or PD-L1 antibody
Description: immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anti-PD-1 or PD-L1 antibody
Description: immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiaotherapy
Description: postoperative radiotherapy (60Gy or 50Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiaotherapy
Description: postoperative radiotherapy (60Gy or 50Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiaotherapy
Description: postoperative radiotherapy (60Gy or 50Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiaotherapy
Description: postoperative radiotherapy (60Gy or 50Gy)
Study: NCT04618484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomodulation (non-pharmacological)
Description: cryo-, photo- and electro-biomodulation
Study: NCT05846464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meta Quest 2
Description: The Meta/Oculus Quest (along with the SignWave software) delivers an immersive audio/visual-based game environment where the users hand is created and displayed in the virtual environment and matches target gestures to the beat of the music.
Study: NCT06290778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Unified Protocol
Description: The Brief Transdiagnostic Treatment of Emotional Disorders Unified Protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation regarding mental health challenges in fire service.
Study: NCT06588101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation
Description: Potential participants are provided an e-gift card to Amazon or Second Cup as a reward for completing the enrollment questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation
Description: Potential participants are provided an e-gift card to Amazon or Second Cup as a reward for completing the enrollment questionnaire.
Study: NCT04725513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy
Description: Participants will receive shockwave therapy once a week for three weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy
Description: Participants will receive shockwave therapy once a week for three weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Description: Participants will receive photobiomodulation therapy twice a week for three weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Participants will enroll in physical therapy and complete an at-home exercise protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Participants will enroll in physical therapy and complete an at-home exercise protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Participants will enroll in physical therapy and complete an at-home exercise protocol
Study: NCT06051357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 tablets
Description: HRS-5965 tablets for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 tablets
Description: HRS-5965 tablets for 12 weeks
Study: NCT05043675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]APN-1607
Description: Subjects will receive one injection of \[18F\]APN-1607 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
Study: NCT06134960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KD-496
Description: Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
Study: NCT05395338

Intervention type: DRUG
Intervention: rt-PA
Description: Recombinant Tissue Plasminogen Activator
Study: NCT04627103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Forming Magnetic (SFM) Anastomosis System
Description: The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
Study: NCT04862377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant Alfa Intratracheal Suspension [Curosurf]
Description: Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg.
Study: NCT06305390

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: 18F-PSMA PET/MRI
Study: NCT06518655

Intervention type: OTHER
Intervention: Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
Description: Detection of volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
Study: NCT04857281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nVNS (gammaCore)
Description: The treatment will be self-administered using nVNS and will be applied for 4 weeks; a member of the study will provide the proper training on the correct use of nVNS. The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
Study: NCT04089111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minute volume target of 100%
Description: Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minute volume target of 100%
Description: Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minute volume target to reach PaCO2 less than 45% (high tidal volume)
Description: Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minute volume target to reach PaCO2 less than 45% (high tidal volume)
Description: Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
Study: NCT05152823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Therapy
Description: AAV9 carrying the IGHMBP2 gene.
Study: NCT06461494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: baseline treatment
Description: hot pack will be applied for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: baseline treatment
Description: hot pack will be applied for 10 minutes
Study: NCT06154265

Intervention type: DEVICE
Group type: OTHER
Intervention: TEE probe
Description: Transesophageal echocardiography, ultrasound probe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEE probe
Description: Transesophageal echocardiography, ultrasound probe
Study: NCT06476509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV232 40mg
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram 20 mg
Description: oral
Study: NCT06256016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck pain massage
Description: Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, effleurages technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck and thoracic massage
Description: Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, deep stroke technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain.
Study: NCT04874194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine Mepesuccinate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05284617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU6
Description: HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05583864

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONDUIT Porous Titanium Spinal Cage
Description: Already included in arm/group descriptions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROTI 360 Titanium-Coated PEEK Spinal Cage
Description: Already included in arm/group descriptions.
Study: NCT06535100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: artistic therapy, wood painting, lithography, jewelry design, mud free shaping, expression workshop and training workshops
Study: NCT04031677

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Large en-bloc curative-intent surgery
Study: NCT04862377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant Alfa Intratracheal Suspension [Curosurf]
Description: Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 0.5 MG/ML
Description: Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide.
Study: NCT04031677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Description: * High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~* LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks~Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same.
Study: NCT05918029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate Extended Release Oral Tablet
Description: Oral potassium citrate extended-release tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule identical to active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate and Citric Acid Oral Solution
Description: Oral potassium citrate and citric acid
Study: NCT06633991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: verbal instructions
Description: verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: verbal instructions
Description: verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)
Study: NCT06571162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacy Team
Description: Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patient will receive usual care for their LDL-C management.
Study: NCT04876144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kogito
Description: Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~1. Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~2. Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~3. CBT - vicious circle, progressive muscle relaxation, peer support content~4. Cognitive distortions, relaxation in imagination, peer support content~5. Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kogito
Description: Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~1. Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~2. Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~3. CBT - vicious circle, progressive muscle relaxation, peer support content~4. Cognitive distortions, relaxation in imagination, peer support content~5. Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks
Study: NCT06557018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: liposomal bupivacaine group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: traditional peri-articular injection
Description: traditional peri-articular injection group
Study: NCT05366517

Intervention type: DEVICE
Group type: OTHER
Intervention: Dornier Aries 2 device
Description: For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
Study: NCT05098899

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MyGeneMyDiet® Recommendations for Weight Management
Description: This group will receive Nutrition and Lifestyle recommendation based on SNPs known to have an impact to body weight and body composition, and responses to physical activity and dietary fat intake
Study: NCT05670704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-119
Description: Patients receiving ARGX-119 IV or SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving Placebo IV or SC
Study: NCT05098899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Standard of Care for Weight Management
Description: This group will receive the conventional and standard nutrition lifestyle recommendation for weight management
Study: NCT06205966

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)
Description: BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
Study: NCT05224414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification for interpretation bias
Description: Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychoeducation
Description: Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
Study: NCT06125548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactation Management Model
Description: The mother provides skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes by hand milking, 2 minutes by breast massage). Head stimulation, stroking for 3 minutes) were asked.
Study: NCT06557135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting (CAS)
Description: CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.